Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... November 17, 2014 Athena Signature Series: Turning ... Dr. Beverly Emerson, a professor in the Regulatory Biology Laboratory ... most recent discovery points to an “off switch” for drug ... and how her local research is making a global impact ... findings and then join host Cheryl K. Goodman, CEO of ...
(Date:11/18/2014)... FL (PRWEB) November 18, 2014 Brothers ... announced the launch of PAWSitively Curing Cancer, Inc ... This new 501(c) (3) non-profit organization is dedicated to ... donated goes directly to the University of Florida ... partner with PAWSitively Curing Cancer as the recipient of ...
(Date:11/18/2014)... INCLINE VILLAGE, Nev. , Nov. 18, 2014 /PRNewswire/ ... ) today announced that in connection with the acquisition ... approximately $42.7 million in connection with the termination of ... the full principal amount outstanding of $40 million, accrued ... October 2013, PDL entered into a structured financing transaction ...
(Date:11/18/2014)... 2014  Novira Therapeutics, Inc., a privately held biopharmaceutical ... hepatitis B virus (HBV) infection, today announced that ... Scientific Advisory Board (SAB).  "We are ... Christian S. Schade , Chief Executive Officer of Novira.  ... will be invaluable to Novira as our lead core ...
Breaking Biology Technology:PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3
... LOUIS, Oct. 16 SAFC Supply Solutions(R),an ... Sigma-Aldrich(TM) group (Nasdaq:,SIAL), has announced that 350 ... now available within its extensive Flavors & ... The Halal certification follows a successful ...
... 15 In only a few days since the,announcement ... received dozens of inquiries from around the world to ... Michigan Virtual BioPharma Company, LLC and the Michigan Virtual,Medical ... launched at an,exhibit at 5:00 p.m. on October 16, ...
... ARBOR, Mich., Oct. 15 Velcura Therapeutics, Inc.,has ... with,more than 20 years of successful regulatory experience, ... President and CEO Michael W. Long, PhD, said,"Jeff ... team. He will be,responsible for our clinical trials ...
Cached Biology Technology:Halal-Certified Products Introduced Into SAFC Supply Solutions' Flavors & Fragrances Food-Grade Line 2Halal-Certified Products Introduced Into SAFC Supply Solutions' Flavors & Fragrances Food-Grade Line 3Michigan Life Science Network: Virtual Companies Get Global Reception 2Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs 2
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... types of personality that affect the extent to which they ... Researchers from Durham University and the University of St ... mothers are often unpredictable and adopt a wide variation of ... Some are very attentive while others are not, the researchers ...
... press release is available in Spanish . ... with beneficial nematodes could improve the delivery, timing and ... The machine is the result of a cooperative ... (USDA) scientists and Southeastern Insectaries, Inc., of Perry, Ga. ...
... the most recent, popular supplements for athletes looking to boost ... called L-arginine. The reason for its popularity is ... "First, L-arginine is a precursor for nitric oxide that ... aid the delivery of important nutrients to working muscles and ...
Cached Biology News:Seals show different levels of parenting skills 2Seals show different levels of parenting skills 3Special delivery: Nematode-infected insect cadavers 2L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3
... microcapillary flow cytometry accessible to anyone in ... appreciate the latest addition to Guavas on-demand ... surprising affordable, and very compact for higher ... features as absolute cell counts, 6 parameters ...
...
... and flexibility of the BDTM LSR, the first UV ... The BD LSR II has performance, capabilities, and ... Free up your high-performance cell sorter by moving your ... LSR II. The BD LSR II can be configured ...
... Accuri's C6 Flow Cytometer System is a full ... system including: the C6 Flow Cytometer, CFlow Software, ... C6 Flow Cytometer System provides all the capabilities ... fraction of the price. The C6 Flow Cytometer ...
Biology Products: